Name
E06 - Reducing Stigma and Empowering Connections: Group Medical Visits in Primary Care Addressing Hidradenitis Suppurativa with Dermatology and Behavioral Health Consultants
Date & Time
Friday, October 25, 2024, 11:15 AM - 11:45 AM
Location Name
Travis A/B
Description

Hidradenitis Suppurativa (HS) is a debilitating inflammatory condition causing painful lesions, often undiagnosed for a decade despite affecting up to 4% of the population, with women of color disproportionately affected. This stigmatizing ailment increases risks of mental health disorders and substance abuse, compounded by challenges accessing interdisciplinary care, especially in rural and marginalized communities. A novel approach integrating dermatology and behavioral health in group medical visits at a rural FQHC offers promise in improving patient experience, outcomes, and healthcare costs, with potential for further quality improvement initiatives and enhanced support for HS patients in primary care.

Speakers
Courtney Valentine PhD, Regional Lead Behavioral Health Consultant, Yakima Valley Farm Workers Clinic, Toppenish, WA
Mengyi Zha MD, FAAFP, Dermatologist, Yakima Valley Farm Workers Clinic, Washington
Courtney Valentine
Co-Authors
Dr. Courtney Valentine and Dr. Mengyi (Zed) Zha
Content Level
All Audience
Tags
Complex Patient Care, Innovations, Medical, Primary Care Behavioral Health Model, Rural, Team-based care, Underserved populations (e.g. LGBTQ)
Session Type
Concurrent
SIG or Committee
JMC, PCBH, Medical
Slideshow link
View Slideshow
Handout 1 Link
View Handout 1
Objective 1
Gaining awareness and understanding of Hidradenitis Suppurativa (HS)
Objective 2
Identify components of Group Medical Visit to address HS
Objective 3
Investigate ways to increase psychoeducation and supports for HS patients in primary care
Content Reference 1

Cunningham SD, Sutherland RA, Yee CW, Thomas JL, Monin JK, Ickovics JR, Lewis JB. Group Medical Care: A Systematic Review of Health Service Performance. Int J Environ Res Public Health. 2021 Dec 2;18(23):12726. doi: 10.3390/ijerph182312726. PMID: 34886452; PMCID: PMC8657170.

Content Reference 2

Shavit E, Alavi A, Bechara FG, et al. Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017. https://doi.org/10.1111/exd.13849. Experimental Dermatology. 2019/01/01 2019;28(1):94-103. doi:https://doi.org/10.1111/exd.13849

Content Reference 3

Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. Journal of the American Academy of Dermatology. 2019;81(1):76-90. doi:10.1016/j.jaad.2019.02.067

Content Reference 4

Garg A, Neuren E, Cha D, et al. Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. Feb 2020;82(2):366-376. doi:10.1016/j.jaad.2019.06.1301

Content Reference 5

Shih T, De DR, Rick J, Shi VY, Hsiao JL. Low Rates of Psychosocial Screening and Lifestyle Counseling in Hidradenitis Suppurativa Patients in the USA. Skin Appendage Disord. 2023 Mar;9(2):94-98. doi: 10.1159/000528253. Epub 2023 Jan 5. PMID: 36937161; PMCID: PMC10015644.